Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is poised for significant growth with its Papzimeos launch momentum, providing a solid foundation for being designated as an HCW 2H26 Top Pick. With projected sales of $27M in 2Q26 and $130M in 2026, the company is well-positioned for cash flow break-even by the end of 2026. In addition, the upcoming ASCO data and label expansion opportunities could further drive adoption of Papzimeos and showcase the potential of Precigen's AdenoVerse pipeline.

Bears say

Precigen is expected to have a negative outlook due to Inovio's significant competition in the RRP market, with their immunotherapy INO-3107 targeting HPV-6 and HPV-11. The FDA's concerns regarding Inovio's accelerated approval for their BLA may also hinder Precigen's market exclusivity and peak penetration, leading to conservative estimates for US sales to only reach $1B in 2033.

Precigen (PGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Precigen (PGEN) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.